Sorkko Thirunavukkarasu, MBBS

Sorkko Thirunavukkarasu practices at USRC Pearlridge Dialysis in Aiea, Hawaii.

Sorkko Thirunavukkarasu's NPI, 1912314626, was assigned on July 14, 2014. Sorkko Thirunavukkarasu holds Hawaii license MD-20883.

Sorkko Thirunavukkarasu's primary practice is USRC Pearlridge Dialysis, at 98-1005 Moanalua Road, Spc 420, Aiea, HI 96701 in Honolulu County. The practice phone is (808) 440-4800.

Sorkko Thirunavukkarasu's primary practice is USRC Pearlridge Dialysis in Aiea, Hawaii. Sorkko Thirunavukkarasu is also affiliated with Pali Momi Medical Center. The medical group on file is Hawaii Kidney Specialists. Dmand AI also links Sorkko Thirunavukkarasu to 4 more hospitals, 2 dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Sorkko Thirunavukkarasu practices, 9 sites in all. Vendor and product names are available with a free account.

Nephrology is Sorkko Thirunavukkarasu's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Sorkko Thirunavukkarasu is licensed in Hawaii.

CMS data shows 1,184 Medicare services from Sorkko Thirunavukkarasu across 9 procedure codes in 2024, for 411 Medicare patients. Medicare paid $121,569 for them.

CMS counts 411 Medicare patients who saw Sorkko Thirunavukkarasu in 2024. The largest group is 75 to 84, with 143 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 14% are also on Medicaid. Their average risk score is 5.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Sorkko Thirunavukkarasu's median patient age at 70, with 45% women.

In 2024, Sorkko Thirunavukkarasu wrote 912 Medicare Part D claims for 202 patients. 70% of them were for generic drugs. CMS names the drug for 746 of them, across 21 drugs with 11 or more claims each, at $317,672 in total drug cost. In 2023, CMS named 690 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Sorkko Thirunavukkarasu for performance year 2024, reported as part of a group. Sorkko Thirunavukkarasu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Sorkko Thirunavukkarasu as offering telehealth.

Dmand AI links 19 papers to Sorkko Thirunavukkarasu, published from 2012 to 2022. 2020 was the busiest year, with 12. The most frequent topics are Hospital Mortality, Acute Kidney Injury and Hypernatremia. Sorkko Thirunavukkarasu has published most often in Int J Clin Pract. Sorkko Thirunavukkarasu's most frequent co-authors are Wisit Cheungpasitporn, MD, Charat Thongprayoon, MD and Michael A. Mao, MD.

CMS Open Payments shows 146 general payments to Sorkko Thirunavukkarasu from 26 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 98% of the total. GlaxoSmithKline, LLC. paid the most, $610.